









104B Cells and Transplantation: An Educational Resource
Trudy N. Small,1 William H. Robinson,2 David B. Miklos2INTRODUCTION
Allogeneichematopoietic cell transplantation (HCT)
offers a unique opportunity to monitor the develop-
ment of immune reconstitution using the patient as
his or her own control. Furthermore, the donor
serves as an HLA-identical normal control and
source of adoptive immune transfer. Donor hemato-
poietic stem cells (HSCs) differentiate and prolifer-
ate to repopulate all blood lineages providing
normal cell numbers of red blood cells, platelets,
and neutrophils. Successful immune reconstitution
and protection from infection requires antimicrobial
B cell and antibody development. Studies of B cell
reconstitution after HCT have primarily examined
immunoglobulin concentration, B cell quantification,
and antimicrobial antibody development in relation
to donor/recipient serologic status or vaccination.
Following HCT, humoral immunity has 3 distinct
contributions. First, recipient antibody persists with an
average half-life of 30-60 days, and some recipient
plasma cells persist for years following allogeneic
HCT [1] providing protective antimicrobial humoral
immunity [2]. Some recipient antidonor alloimmune
responses are detrimental contributring to primary
graft rejection [3,4] and prolonged red cell aplasia
when donors and recipients are ABO major mis-
matched [5,6]. Second, donor grafts contain naı¨ve
and memory B cells that have already undergone
positive and negative selection in the HLA-identical
donor and contribute adoptive antimicrobial and allor-
eactive B cells. Third, B cells reconstituting from do-
nor HSCs recognizing disparate recipient antigens as
‘‘self’’ will be clonally deleted, preventing alloreactive
responses, but remain capable of responding to infec-
tious challenges and vaccinations. This educational
session will consider B cell responses following alloge-1Department of Pediatrics and Clinical Laboratory Med-
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antimicrobial immunity, (2) autoimmune responses,
and (3) allogeneic antibody responses. We will discuss
a B cell role in chronic graft-versus-host diease
(cGVHD) pathogenesis, review anti-B cell cGVHD
therapy using rituximab, and, finally, consider the
pathogenic role of agonistic antibodies targeting plate-
let-derived growth factor receptor (PDGFR).Normal B Cell Ontogeny
B cell development is schematically depicted in
Figure 1. Progenitor B cells receive signals from essen-
tial bonemarrow stromal cells via cell-cell contacts and
secreted signals. Stem cell factor (SCF) on stromal cell
membranes binds ckit (CD117) on the lymphocyte
membrane, and secreted cytokines, especially interleu-
kin (IL)-7, promote B cell development [7-9]. B cells
bind antigen with varying affinity through B cell recep-
tors that gain diversity through intrachromosomal var-
iable (V) and constant (C) region recombination [10]. B
cell positive selection requires tonic signaling through
membrane pre-B receptor and membrane IgM expres-
sion for the B cell to survive. Mouse knock-out exper-
iments expressing null alleles of the heavy chain
transmembrane exon, Iga or Igb genes, or their ITAMs
prevents B cell development [11,12]. Likewise, produc-
tive somatic recombination leads to allelic exclusion for
both heavy and light chains in each individual B cell. B
cells recognizing self antigens are negatively selected
before emerging from the bone marrow.
Accumulating data suggests the BCR affinity
‘‘threshold’’ is influenced by cytokine tumor necrosis
factor (TNF) family member B cell-activating factor
(BAFF; also termed BLyS). Three receptors have
been identified that bind to BAFF: transmembrane ac-
tivator, calcium modulator, and cyclophilin ligand in-
teractor (TACI); B cell maturation Ag (BCMA); and
BAFF-R. Baff-R(2/2) mice mount significant, but re-
duced, Ag-specific Ab responses [13]. BAFF and its re-
ceptors, play a crucial role in peripheral B cell selection
and survival, by dictating the set point for the number
of mature primary B cells and adjusting thresholds
for specificity-based selection during transitional dif-
ferentiation [14,15]. Transgenic models demonstrate
that antigen-induced anergy and exclusion from follic-





























Figure 1. B cell maturation profile.
Biol Blood Marrow Transplant 15:104-113, 2009 105B Cells and Transplantationpresence or absence of a diverse B cell pool [16]. In ad-
dition, B cell reconstitution and homeostasis after
myeloablation requires the B survival factor BAFF
[17]. Limiting amounts of BAFF are required for on-
going B cell turnover and avoidance of B cell autoreac-
tivity [18]. This is because in the setting of a limited B
cell pool, excess BAFF promotes the survival of autor-
eactive B cells [19]. These BAFF homeostatic demands
suggest a paradigm that unites peripheral negative and
positive selection with the maintenance of mature B
cell numbers [20,21] that probably have an impact on
post-HCT reconstitution. Plasma BAFF levels are
markedly elevated following myeloablative condition-
ing and decrease as lymphocyte numbers recover. Ele-
vated BAFF has been associated with cGVHD [22] and
autoimmune diseases [23-25].
Antibody Reconstitution after HCT
Early studies showed IgG and IgM return to nor-
mal concentrations 3-4 months after allogeneic HCT
[26,27], whereas B cells are quantitatively deficient
during the first month and persists in some patients
for more than a year after allo-HCT [28-30]. Antibody
assessment is complicated by blood product support
transferring significant immunoglobulin and antibody
half-life extending 30-60 days. Nonetheless, vaccina-
tion with neoantigens phage 4X174 and keyhole lim-
pet hemocyanin (KLH) demonstrated effective IgG
responses 6 months after HCT, but antibody response
lagged in patients with cGVHD or those who received
antithymocyte globulin (ATG) [31]. A reduced immu-
noglobulin repertoire persists for at least 2 years after
HCT with oligoclonal dominance [32,33]. The diver-
sity of heavy IgG VDJ gene rearrangement reflects a
broad adultm-chain useage arguing against a recapitula-
tion of fetal ontogeny [34]. Post-HCT IgH repertoire
is characterized by decreased somatic hypermutation
[35], delayed class-switching [36], and oligoclonal
dominance [37,38].
Analysis of herpes simplex virus (HSV) and cyto-
megalovirus (CMV)clarified that antiviralAb responseswere of recipient origin for the first year post-HCT
[2,39,40]. Persistent high-titer IgG responses persisted
when recipients were seropositive and donors seroneg-
ative, and likewise recipients remained seronegative
even when the donor was seropositive unless viral
infection erupted [41].Deliberate vaccinationof donors
pretransplant with a protein recall antigen, such as
tetanus toxoid [42], or neoantigen KLH [43], could
demonstrate adoptive B cell transfer but antibody de-
velopment still required recipient revaccination after
transplant.
Donor and Recipient Antibody Contribution
Can Be Distinguished by Allotype
Allotype-specific monoclonal antibodies (mAbs)
specifically bind single amino acid polymorphisms
located in the immunoglobulin constant fragment of
specific IgG isotypes [44]. If either the donor or recip-
ient is homozygous null for an allotype then the HCT
pair is informative allowing antibody origin to be deter-
mined. For example, if the recipient is null for IgG1
detection using allotype reagent, then the development
of donor derived IgG1 is allotype detected. Such allo-
type reagents provided the first evidence of donor B
cell reconstitution after HCT [45], and that some re-
cipient plasma cells persist for years aftermyeloablative
HCT. In a pediatric study, 8 of 13 informative pairs
showed some persistent recipient IgG more than
a year and some 8 years after myeloablative allogeneic
HCT [1]. More recently, IgG allotype studies showed
recipient antimicrobial IgG predominates following
reduced-intensity conditioning (RIC)HCT, andDNA
chimerism confirmed that themajority of bonemarrow
plasma cells remained recipient derived 1 year after
RIC allo-HCT [46]. In support of this recipient hu-
moral immunity predominance, a study of 87 patients
randomized to receive either marrow or peripheral
blood stem cells (PBSCs) showed vaccine-specific anti-
body responses in the first year after allo-HCT re-
flected primarily the recipient’s pretransplant titer
[47]. Thus, humoral immunity is predominately
106 Biol Blood Marrow Transplant 15:104-113, 2009T. N. Small et al.recipient derived for the first year after RIC allogeneic
HCT, and this persistent recipient derived antimicro-
bial IgG may benefit RIC allo-HCT patient and con-
tribute to their decreased treatment related mortality
(TRM).
Immunogenicity of Vaccines following HCT
Vaccine preventable infections, such as pneumo-
coccus [48], influenza [49], and varicella [50] remain
a significant cause of morbidity, rehospitalization,
and mortality after successful HCT. Despite the fact
that influenza infections remain a significant cause of
serious upper and lower respiratory tract infections
post-HCT, many patients do not receive their yearly
influenza immunization. Most studies report a 30%
to 40% incidence of reactivation of varicella zoster vi-
rus (VZV) following HCT. In a retrospective study of
100 consecutive allogeneic HCT recipients, 41% de-
veloped a VZV infection at a median of 227 (range:
45–346) days posttransplantation [50]. Forty percent
of patients required admission to the hospital, with
a mean stay of 7.2 days. Postherpetic neuralgia and pe-
ripheral neuropathy developed in 68% of patients [18].
As such, revaccinating HCT patients prevents signifi-
cant morbidity and mortality, and, in addition, well-
designed vaccine studies functionally assess B cell
immune reconstitution.
Protective Immunity Dissipates after
Myeloablative HCT
Multiple studies have demonstrated that in the ab-
sence of revaccination, both autologous and allogeneic
transplant recipients lose seroprotection to pathogens
they were immunized against during childhood (re-
viewed in [51,52]). Although there is some variability
in the time to protective titer loss among different
transplant groups, loss of pneumococcal, H flu, and
tetanus titers usually occur by 2 years post-HCT [53].
Residual titers against measles, mumps, and rubella
persist longer after HCT [54]. These vaccine studies
showing the loss of humoral immunity studiedmyeloa-
blative HCT patients, therefore, RIC studies are
needed.
Vaccine Lessons
Repetitive vaccination improves efficacy
Following an HLA matched related bone marrow
transplant (BMT), Ljungman et al. [55] showed that
42%, 36%, and 21% of patients immunized with 1 in-
activated polio virus vaccine (IPV) developed a 4-fold
rise in titer against serotypes 1, 2, and 3, respectively.
Following 3 doses, 50% of patients responded to all
3 serotypes. In contrast, Parkkali et al. [53] reported
a 100% rate following 3 IPV whether administered
at 6, 8, and 14 months (n 5 23) or at 18, 20, and 26months (n5 22). AtMemorial Sloan Kettering Cancer
Center (MSKCC), 96% of 219 allogeneic HCT recip-
ients responded to a series of 3 IPV when administered
following acquisition of minimal milestones of im-
mune competence (CD4 .200/mL, PHA within 10%
of normal, IgG .500 mg/dL) [56]. There was no dif-
ference in response in related or unrelatedHCT recip-
ients, or those who received a T cell-depleted or T
cell-replete HCT. The range of responses in these 3
studies may reflect in part variable levels of immune
competence at the time of revaccination.Vaccine efficacy varies by glycosylation and
conjugation
Although most transplant patients respond well to
vaccines containing bacterial toxoids, response to pure
polysaccharide vaccines has been poor [57-60]. Barra
et al. [57] demonstrated that only 4 of 20 (25%) adult
allogeneic transplant recipients immunized with a sin-
gle nonconjugated H flu vaccine developed a specific
IgG response compared to 11 of 20 patients recipients
1 H flu conjugate vaccine (Hib) (P\ .05). Most studies
have also shown that\25% of HCT recipients are ca-
pable of responding to the polyvalent polysaccharide
vaccine, PPV23 [57-59], as well as no benefit of donor
vaccination with PPV23 prior to stem cell donation
[60]. Limited response to polysaccharide antigens
post-HCT may be because of the predominance of
immature B cells expressing CD1c, CD5, CD38,
CD231, B cells similar to the circulating B cells de-
tected in cord blood and young children [29]. Limited
responses may also reflect deficits in CD271 memory
B cells, a subset that may take years to recover even
in children following HCT [61]. Nonetheless, heavy-
chain IgG sequence analysis of Hib-specific B cells
collected after Hib revaccination 9 months after
myeloablative allogeneic BMT showed unique pat-
terns of hypermutation, suggesting 90 of 121 (74%)
were derived from only 16 precursors, and 12 of these
clones were identified in the donor [62]. Thus, this
single-patient study suggests memory B cells specific
to Hib were transferred from the donor, persisted 9
months, and contributed the majority of Hib-specific
repertoire.
In contrast to the poor response to polysaccharide
vaccines, response to protein-conjugated polysaccha-
ride vaccines is significantly better, and can be en-
hanced by donor vaccination prior to the stem cell
harvest [63,64]. Meisel et al. [65] showed a 74% re-
sponse to the 7 serotypes contained in PCV7 in 43 pa-
tients \17 years of age immunized with 3 PCV7
starting at 6 months following a related or unrelated
HCT. A retrospective study of PVC7 and Hib re-
sponses in 127 patients immunized at MSKCC also
demonstrated a decline in PCV7 response with ad-
vancing age [66]. Forty-five of 51 patients\18 years
Table 1. Consensus Vaccination Guidelines
Vaccine CDC EBMT
Td, IPV, Hib 2 doses Started 12m 3 doses Started 6-12m
PPV23 12 m, 24 m 12m
HepB Optional Recommended
























































Figure 2. Median number of CD191 B cells/mL peripheral blood after
allogeneic HCT. Kindly provided by Trudy Small.
Biol Blood Marrow Transplant 15:104-113, 2009 107B Cells and Transplantationof age responded to PCV compared to 34 of 76 adults
(P\ .001). Although PCV7 response was adversely af-
fected by older age (P\ .001), individuals $50 years
old responded significantly better if vaccinated follow-
ing acquisition of specific minimal milestones of im-
mune competence, CD4 .200/mL, IgG .500 mg/
dL, or PHA within 60% lower limit of normal (11 of
19 versus 0 of 8, P\ .006). A similar trend was ob-
served in patients with limited cGVHD. Each of these
studies demonstrates that PCV7 is immunogenic in
HCT patients, including older adults, but suggest
that vaccination timing might depend on immune
competence for best vaccine response.
Vaccine efficacy is predicted by recipient immune
reconstitution status
Revaccination against hepatitis B is mandatory for
reentry to school and certain workplaces. Machado
et al. [67] reported a 100% seroconversion rate in 50
HCT recipients immunized at least 1 year after trans-
plant. Despite this excellent initial response, 60% of
patients failed to sustain titers for more than 1 year
after vaccination. MSKCC evaluated the response of
267 allogeneic transplant recipients immunized with
rHBV following acquisition of minimal milestones of
immune competence [56]. Sixty-four percent of pa-
tients seroconverted, including 73% of 99 children
and 59% of 168 adults (P 5 .02). In multivariate anal-
yses, response was adversely affected by age .18 years
(P\ .01) and history of prior cGVHD (P\ .0001).
Eighty-two percent of 99 evaluated patients remained
seropositive 5 years following their last vaccine. This
greater proportion of patients with sustained hepatitis
B titers in the MSKCC (82%), compared to Machado
and colleaugue’s study (40%), suggests qualitative and/
or quantitative differences in the circulating memory
T and/or B cells present at the time of vaccination.
Surrogate markers of immune competency may be
necessary in determining the need and timing of
booster immunizations to maintain durable protective
titers following vaccination.
Vaccine guidelines
The above data demonstrates that unlike vaccina-
tion in healthy individuals, vaccination post-HCT
does not ensure seroprotection, emphasizing the
need to document pre- and postvaccine titers to deter-
mine response. Although vaccination of patients with
limited or no cGVHD will likely respond well to im-
munization starting 6 months post-HCT, how best
to protect patients requiring steroids 6 other immu-
nosuppressive agents, is currently not known. Table 1
presents the consensus vaccination guidelines of the
Center for Disease Control (CDC) [57] and the Euro-
pean Blood and Marrow Transplant [58], and Center
for International Blood and Marrow Transplant Re-search (CIBMTR) guidelines will soon be issued. Pro-
spective trials documenting the efficacy of these
guidelines to protect the growing numbers of trans-
plant survivors are needed.
B cell Reconstitution following Allogeneic HCT
Quantitative B cell deficiency in peripheral blood
has long been noted in the first month after HCT
and can persist for years being worsened by cGVHD
and/or the treatment of cGVHD [28-30,70]. Figure 2
shows that peripheral blood CD191 B cell reconstitu-
tion in pediatric and adult recipients has similar kinet-
ics but varies by graft source with T cell depleted bone
marrow products preceeding unmanipulated, T cell
replete bone marrow grafts (T. Small data).
Peripheral blood B cell development is currently
characterized by 4 surface markers: CD19, IgD,
CD38, and CD27 immunophenotyping. The results
of normal donor CD191 gated B cells are presented
as 2-dimensional comparison of IgD versus CD38 in
Figure 3. The IgD versus CD38 comparison provides
the Bm1-Bm5 classification that identifies: (a) virgin
naı¨ve cells (IgD1CD382), (c) pregerminal center cells
or transitional (IgD1CD3811), (b) postgerminal cen-
ter memory cells (IgD2CD381/2), and (d) germinal
center plasmablasts (IgD2CD3811), reviewed [71].
The IgD vervus CD27 classification provides meaning
because CD27 is the universal marker of ‘‘memory’’
and thus distinguishes between CD272IgD1 naı¨ve
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Figure 3. Peripheral B cell immunophenotyping based on the expression of IgD and CD38 shows normal donor peripheral blood B cells are mostly
nay¨ve.
108 Biol Blood Marrow Transplant 15:104-113, 2009T. N. Small et al.cell, and CD271IgD2 ‘‘isotype switched’’ memory
cells. Increased CD27 expression on human B cells is
known to correlate with commitment to the plasma
cell lineage [72]. B cells develop in bone marrow
and the immunophenotype of the earliest bone
marrow emigrant to the peripheral blood is the
IgD1CD381CD272 ‘‘transitional’’ cell, which is the
precursor to the ‘‘naı¨ve’’ mature IgD1CD382 cell.
Progression thenmoves to pregerminal center founder
(Pre-GC) CD271 and postgerminal center memory
cell. Both the pre-GC and post-GC can become
IgD2 isotype switched plasmablasts. The pre-GC are
IgD1CD38HiCD271 cells are typically found in hu-
man tonsils [73], and have been shown to circulate
with increased frequency in systemic lupus erythema-
tosis (SLE) patients [74,75]. Sarantopoulos et al. [76]
analyzed peripheral CD271 B cell subsets in 57 post-
HCT patients and healthy controls by performing 4
color-flow cytometry analyses. CD271 was increased
on all IgD versus CD38 populations in patients with
cGVHD compared to patients without cGVHD.
Pre-GC B cells were more prevalent in patients
with active cGVHD than those without cGVHD
(P 5 .06) [76].
A longitudinal study of 139 pediatric HCT recipi-
ents undergoing myeloablative (119 allogeneic) HCT
showed recovering B cells at 3, 6, and 12 months after
HCT are predominately naı¨ve (IgD1CD271), and
consequently, a significantly lower percentage of both
‘‘class able to switch’’ (IgD1CD271) and ‘‘classswitched’’ (IgD2CD271) B cells when compared to
age-matched controls [63]. Even at 18 to 24 months
after HCT there was a significant number of patients
with CD271memory cells less than the fifth percentile
of normal controls. As predicted by the lack of memory
B cells, an in vitro T cell-independent polyclonal stim-
ulation revealed reduced IgG production, which has
also been reported in adults [70]. Neither B cell subset
distribution nor stimulated Ig production correlated
with source of stem cells, type of conditioning, immune
suppression, or the development of acute GVHD
(aGVHD) or cGVHD. Avanzini et al. [63] propose
that germinal center B cell reactions are disturbed
post-HCT possibly because of lymph node histoarch-
itectural damage. Additional B cell immunophenotyp-
ing studies may identify abnormal developmental
immunophenotypes especially in the setting of elevated
BAFF possibly accounting for autoantibody produc-
tion and functional immune deficiencies after HCT.B Cells and cGVHD
Mouse studies suggest a role for B cells in the
development of scleroderma and cGVHD. B lym-
phocytes have been implicated in cutaneous sclerosis
in both murine and human studies. The tight skin
(Tsk/1) mouse has a tandem duplication within the fi-
brillin-1 (FBN1) gene and heterozygous mice exhibit
increased collagen and other matrix protein deposits
in their skin [77]. If bone marrow and splenocytes are
Biol Blood Marrow Transplant 15:104-113, 2009 109B Cells and Transplantationtransplanted from Tsk/1 donors into normal mice,
a scleroderma phenotype and autoantibodies develop
[78,79]. B cell depletion using an antimouse CD20
mAb before or 3 days after birth suppressed skin fibro-
sis by 43% and autoantibody production [80]. Studies
in minor histocompatibility antigen mismatched
mouse models of cGVHD support involvement of B
cells in its pathogenesis [81-83].
In humans, Miklos et al. [84] demonstrated alloge-
neic antibodies against at least 1 Y chromosome en-
coded protein (H-Y antigen) developed in 52% of
female / male recipient HCT tested by ELISA
against a 5 H-Y antigen panel: DDX3y, UTY, ZFY,
RPS4Y, and EIF1AY. In the presence of antibodies
to at least 1 H-Y protein, the cumulative incidence of
cGVHD reached 89% at 5 years after transplantation
compared to only 31% in the absence of H-Y anti-
bodies (P\ .0001) [85]. The concordant development
of allogeneic H-Y antibodies and chronic GVHD pro-
vided early evidence for an important B cell role in
chronic GVHD pathogenesis.
A possible role for elevated soluble BAFF in
cGVHD is plausible because high BAFF levels are
found in patients with autoimmune diseases [25,86],
including scleroderma [87], and murine models of B
cell autoimmunity. Inmice, both normal and autoreac-
tive B cell development depends on the relative balance
of B cell receptor (BCR) and BAFF signaling [88-92].
In the setting of a limited B cell pool, excess BAFF pro-
motes the survival of autoreactive B cells [19]. Saranto-
poulos et al. [22] studied BAFF levels in 104 allogeneic
HCT patients and showed BAFF levels were signifi-
cantly higher in patients with active cGVHD, com-
pared to those without disease (P 5 .0002). Serial
testing of 24 HCT patients showed BAFF levels
were high in the first 3 months following HCT, but
subsequently decreased in 13 patients who never devel-
oped cGVHD. In contrast, BAFF remained elevated in
11 patients who developed cGVHD. BAFF .10 ng/
mL 6 months after allogeneic HCT was strongly asso-
ciated with subsequent cGVHD development [22].
One complication of this analysis is that BAFF levels
are suppressed in patients receiving more than 30 mg
of prednisone daily, and prednisone is almost always
used to treat aGVHD and cGVHD.
Rationale for Rituximab Treatment of cGVHD
Rituximab, a humanized IgG1 antibody against
CD20, depletes B cells and is effective in treating pa-
tients with steroid-refractory cGVHD. Cutler et al.
[91] reported a phase I clinical trial testing Rituximab
in 21 patients with steroid-refractory cGVHD. Ritux-
imab (375 mg/m2/week  4 weeks) was given with an
option for a second course for non- or partial re-
sponders. Rituximab was well tolerated, and objective
responses were noted in 13 of 20 patients (70%, pri-
marily cutaneous and rheumatologic). CD191 B cellswere undetectable in all peripheral blood samples for
9 to 12 months; median serum IgG levels fell 37%,
but protective IgG antibody responses against epstein
barr virus (EBV) EBNA1 and tetanus toxoid remained
unchanged in 17 out of 18 patients. Antibody titers
against H-Y antigens decreased after rituximab ther-
apy and remained low for a year after treatment. All
4 patients with demonstrable H-Y antibodies had
clinical responses to rituximab therapy [93].
Zaja et al. [94] reported a 65%overall response rate
in 38 patients with steroid-refractory cGVHD treated
with rituximab. Skin was the most likely to respond
(63%) followed by mouth (48%), eyes (43%), lung
(38%), and liver (25%). Infections were the major
complication. Mohty et al. [95] treated 15 severe or
steroid refractory cGVHD patients with rituximab
weekly for 4 weeks, and responders received 1 to 2
courses of maintenance rituximab. With a median fol-
low-up of 118 days from first rituximab infusion, no
major toxicities were ascribed to rituximab. Overall,
10 patients (66%) responded, and 3 achieved complete
responses. Four patients did not respond and died of
refractory cGVHD.
As shown schematically in Figure 1, CD20 (devel-
opmental expression of CD20 shown in red) is first ex-
pressed on B cells after they have undergone heavy-
and light-chain recombination and express IgM BCR
on their cell surface, a stage called ‘‘immature B cells.’’
CD20 continues to be expressed until the cell becomes
an immunoglobulin secreting plasma cell. T cell-de-
pendent human plasma cells in secondary lymphoid
tissue are CD201 [96]. Thus, rituximab treatment
postallogeneic HCT may potentially eliminate
CD201 alloreactive cells while leaving early pre- and
pro-B cells to develop into nonalloreactive mature B
cells. Rituximab therapy is well tolerated with rela-
tively few infectious complications [93] because long-
lived host plasma cells continue to secrete protective
antimicrobial antibodies [97].
Autoantibodies Are Associated with Systemic
Sclerosis
Systemic sclerosis involves progressive fibrosis
with obliteration of small artery lumens as well as
humoral immunologic dysregulation associated with
hypergamaglobulinemia and antinuclear antigen anti-
bodies (ANA) [98]. These autoantibodies include
antitopoisomerase I (Scl70), anticentromere, anti-
RNA polymerase III, anti-U3-fibrillarin, and others
[99]. However, despite their association with sclero-
derma, these ANA have not been shown to be patho-
genic. Other autoantibodies targeting extracellular
matrix proteins include: antifibrillin-1 (anti-FBN1)
[100] and antimatrix metalloproteinases (MMP), such
as MMP1 (interstitial collagenase) [101] and MMP3
(stromelysin) [102]. FBN1 is a 350-kDa glycoprotein
that is the major constituent of microfibrils in the
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growth factor (TGF)-b. Anti-FBN-1 antibodies are
present in the majority of scleroderma patients, and
some authors suggest anti-FBN1 antibodies may
release TGF-b, which can then activate fibroblasts
promoting fibrosis [103,104].
Because the clinical manifestations of cGVHD
share many features with scleroderma [105], cGVHD
patients have been repeatedly examined for autoanti-
body development with inconsistent results. Some
studies suggest autoantibodies develop in association
with cGVHD [106,107], whereas others show autoan-
tibodies develop as frequently as 25% after allogeneic
transplantation but occur equally in patients with and
without cGVHD [108].
Antibodies against PDGFR Associate with
Systemic Sclerosis and cGVHD
Fibroblasts have been extensively investigated as
the target of autoantibodies in patients with sclero-
derma [109]. PDGF receptors are upregulated in the
skin and bronchoalveolar lavage fluid in scleroderma
[110]. In 2006, Svegliati et al. [111] reported 46 patients
with systemic sclerosis had stimulatory antibodies
against PDGFR. These antibodies were absent in 20
healthy controls and another 55 patients with a variety
of other rheumatologic conditions. In another study,
agonistic PDGFR antibodies were detected in 22
allogeneic HCT patients with extensive cGVHD.
Anti-PDGFR antibodies were not detected in 17
HCT patients without cGVHD and 20 normal con-
trols [112]. These PDGFR-a antibodies induced tyro-
sine phosphorylation, accumulation of reactive oxygen
species (ROS), and type 1 collagen gene expression
through theHa-Ras-ERK1/2-ROS signaling pathway,
all processes implicated in inflammation and fibrosis
[113]. PDGFR antibodies are relatively long lived
compared to the 15-minute half-life of PDGF itself.
Thus, anti-PDGFR agonistic antibodies may be
the pathogenic cause of sclerosis in some cGVHD pa-
tients, and drug inhibition of PDGFR signaling is
a promising treatment for sclerosis. This might be
achieved through either direct tyrosine kinase inhibi-
tion of PDGFR or anti-B cell therapy that eliminates
the agonistic anti-PDGF antibody. Drs. Lorinda
Chung and Bill Robinson have initiated a phase I clin-
ical trial of imatinib treatment of systemic sclerosis
with promising preliminary results (Chung et al, man-
uscript submitted). Immunohistochemical analysis of
serial skin biopsies obtained before and 1 month after
imatinib 200 mg/day treatment show decreased anti-
phospho-PDGFR antibody staining in the setting of
clinical improvement. Extending this treatment strat-
egy to cGVHD, the Italian bone marrow transplant
cooperative group, GITMO, reported a safety and tol-
erability study of imatinib (100-200 mg daily) for
cGVHD as an abstract at the European Bone MarrowTransplant Meeting in April 2008 [114]. They re-
ported an overall response of 86% with a follow-up
of 8months. Aspects of cGVHD that responded to im-
atinib included sclerodermatous disease, chronic bron-
chiolitis, and osteomyalgia. Toxicity was evaluated at 3
and 6 months. Four of 15 subjects experienced minor
extrahematologic toxicity and 1 of 15 experienced
grade 3-4 toxicity. Taken together, the frequent asso-
ciation of cGVHD and anti-PDGFR antibody and re-
ported imatinib safety and tolerability in cGVHD
patients supports further imatinib efficacy trials to
determine cGVHD response rate and confirm its
mechanism of action.Future Directions
Protective antimicrobial immunity and allogeneic
immune responses ultimately results from the recon-
stitution of donor lymphocytes with diverse T and B
cell repertoires following allogeneic HCT. Nonethe-
less, humoral immunity immediately post-HCT is
predominately recipient derived. Over the past 10
years, RIC regimens have decreased treatment-related
mortality (TRM) and extendedHCT to older patients.
The success of these RIC allogeneic HCT relies pri-
marily on developing beneficial allogeneic immune
responses, graft-versus-leukemia/lymphoma (GVL),
and effective protective immune reconstitution. Al-
though RIC regimens have succeeded in decreasing
TRM and aGVHD incidence, cGVHD remains prob-
lematic. One key difference between high-dose condi-
tioning and RIC is the dynamic balance between the
decreasing host-versus-graft (HVG) resistance to en-
graftment and the developing graft-versus-host (GVH)
immune responses. Although myeloablative HCT
causes rapid conversion to full donor T and B cell chi-
merism, RIC patients’ progress through a transient
mixed chimerism extending weeks to months, and the
pace of transition differs by conditioning regimen
[115]. Thus, we believe an improved understanding of
B cells and serologic immune responses following
RIC HCT in relation to antimicrobial immunity,
GVL, and GVHD are critical. Future vaccine studies
will functionally asses B cell immune reconstitution
following RIC allogeneic HCT thereby decreasing
patients’ infectious complications and revealing B cell
transplant biology. B cell immunophenotyping, heavy-
chain IgG repertoire analysis, and B cell functional
assays combined with multiplexed serologic antigen
binding assays promises to identify allogeneic antibody
and B cell contributions to both GVL and GVHD.ACKNOWLEDGMENTS
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